| 5.02 0.16 (3.29%) | 10-28 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.12 |
1-year : | 7.14 |
| Resists | First : | 5.23 |
Second : | 6.12 |
| Pivot price | 4.7 |
|||
| Supports | First : | 4.55 |
Second : | 4.13 |
| MAs | MA(5) : | 4.63 |
MA(20) : | 4.73 |
| MA(100) : | 5.36 |
MA(250) : | 5.41 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 72.8 |
D(3) : | 46.2 |
| RSI | RSI(14): 54.4 |
|||
| 52-week | High : | 7 | Low : | 3.85 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ SVRA ] has closed below upper band by 9.8%. Bollinger Bands are 6.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.06 - 5.08 | 5.08 - 5.1 |
| Low: | 4.73 - 4.75 | 4.75 - 4.77 |
| Close: | 4.99 - 5.02 | 5.02 - 5.06 |
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.
Fri, 23 Oct 2026
Savara, Inc. Estimates – NASDAQ:SVRA - TradingView
Tue, 13 Oct 2026
Molgramostim Data Preview Could Be A Big Test For Savara Stock (SVRA) - Simply Wall St
Tue, 13 Oct 2026
Will Long‑Term Molgramostim Data at CHEST 2026 Change Savara's (SVRA) Autoimmune PAP Narrative? - Yahoo Finance
Wed, 05 Aug 2026
Savara: High-Potential Binary Bet Cruising To PDUFA After A 3 Month Speed Bump (SVRA) - Seeking Alpha
Sat, 01 Aug 2026
$5.38 | Savara Inc. Common Stock (SVRA) Stock Price Today - Binance
Fri, 26 Jun 2026
SVRA Forecast — Price Target — Prediction for 2027 - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 205 (M) |
| Shares Float | 130 (M) |
| Held by Insiders | 2.5 (%) |
| Held by Institutions | 106.8 (%) |
| Shares Short | 43,560 (K) |
| Shares Short P.Month | 41,430 (K) |
| EPS | -0.58 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.56 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -50.2 % |
| Return on Equity (ttm) | -105.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.43 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.7 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -110 (M) |
| Levered Free Cash Flow | -57 (M) |
| PE Ratio | -8.66 |
| PEG Ratio | 0 |
| Price to Book value | 8.96 |
| Price to Sales | 0 |
| Price to Cash Flow | -9.35 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|